EXEL vs. VTRS: Exelixis vs. Viatris Stock Comparison

November 11, 2026

How do Exelixis (EXEL) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Viatris (VTRS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while VTRS is classified in Pharmaceuticals.

Company profile comparison for Exelixis (EXEL) and Viatris (VTRS)
Profile Item	EXEL	VTRS
Name	Exelixis Inc.	Viatris Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	16.98 billion USD	22.83 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	April 17, 2000	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

EXEL

VTRS

GSPC

Exelixis (EXEL) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Exelixis (EXEL) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Exelixis (EXEL) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Total Return (1Y)	74.98%	108.98%
Total Return (3Y, Annualized)	50.33%	36.75%
Total Return (5Y, Annualized)	31.10%	11.59%

Risk Profile

Drawdown History

EXEL

VTRS

GSPC

Exelixis (EXEL) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Exelixis (EXEL) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Volatility (1Y, Annualized)	34.17%	32.53%
Beta (5Y)	0.41	0.86
Max Drawdown (5Y)	-35.41%	-45.69%
Avg. Volume (3M)	2.33M	8.87M

Risk-Adjusted Performance

Risk-Return Positioning

EXEL and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Sharpe Ratio (1Y)	2.07	3.22
Sortino Ratio (1Y)	3.23	5.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Exelixis (EXEL) reports 44.32%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max: 109.18%
EXEL: 44.32%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Exelixis (EXEL) reports 35.45%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL: 35.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Exelixis (EXEL) at 40.75% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max: 83.12%
EXEL: 40.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
ROE (TTM)	44.32%	-4.21%
ROA (TTM)	23.52%	2.91%
Net Margin (TTM)	35.45%	-4.13%
Operating Margin (TTM)	40.75%	13.85%
Gross Margin (TTM)	96.26%	41.13%

Growth

Revenue Growth

Exelixis (EXEL) at 6.98% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Exelixis (EXEL) reports EPS growth of 57.95%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Revenue Growth (YoY)	6.98%	-2.98%
Revenue Growth (3Y CAGR)	12.93%	-4.20%
EPS Growth (YoY)	57.95%	--
EPS Growth (3Y CAGR)	70.59%	--

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Viatris (VTRS) at 1.55 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VTRS.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max: 25.13
Q3: 12.13
Median: 5.52
EXEL: 3.21
Q1: 2.47
Min: 0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Exelixis (EXEL) at 0.09 carries an industry-typical debt-to-equity mix, while Viatris (VTRS) at 0.99 uses more debt funding than most peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max: 1.42
Q3: 0.65
Median: 0.15
EXEL: 0.09
Q1: 0.02
Min: 0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Current Ratio (MRQ)	3.21	1.55
Debt / Equity (MRQ)	0.09	0.99
Net Debt / EBITDA	-0.71	2.64

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Viatris (VTRS) reports a yield of 2.53%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings; Exelixis (EXEL) pays no dividend (payout 0.00%).

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
Dividend Yield (TTM)	0.00%	2.53%
Dividend Payout Ratio (TTM)	0.00%	960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Exelixis (EXEL) trades at 20.83 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max: 85.34
Q3: 43.46
Median: 26.69
EXEL: 20.83
Q1: 13.30
Min: 0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

Exelixis (EXEL) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; EXEL is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Exelixis (EXEL) at 6.80 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max: 58.18
Q3: 25.77
Median: 7.30
EXEL: 6.80
Q1: 3.01
Min: 0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 looks cheap against book in the lower P/B ratio quartile, while Exelixis (EXEL) at 9.28 carries a premium in the upper quartile — a clear price-to-book gap.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max: 13.53
EXEL: 9.28
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

Exelixis (EXEL) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Viatris (VTRS)
Metric	EXEL	VTRS
P/E Ratio (TTM)	20.83	--
P/S Ratio (TTM)	6.80	1.55
P/B Ratio (MRQ)	9.28	1.67
Free Cash Flow Yield (TTM)	4.47%	13.84%